Abbreviations: ART, antiretroviral therapy; CHB, chronic hepatitis B; CI, confidence interval; HBsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma; IQR, interquartile range; MSM, men who have sex with men; PLHIV, people are living with HIV; PWID, people who inject drugs.
| INTRODUC TI ON
Chronic hepatitis B (CHB) infection, defined as persistence of hepatitis B surface antigen (HBsAg), is a major public health problem resulting in an estimated 900 000 deaths in 2015. [1] [2] [3] [4] Although HBV can be prevented with vaccination, in 2015, there were an estimated 257 million persons chronically infected. 4 Between 20 and 30% of those with chronic infection develop complications, mainly cirrhosis and hepatocellular carcinoma (HCC). 5 CHB accounts for 43% of cases of HCC and 40% of cirrhosis, with much higher proportions in lower middle-income countries, 4 and 5%-10% of liver transplants in high-income countries. 6 Age is a key determinant of the risk of chronic infection: chronicity is common following acute infection in neonates (around 90%) and young children under the age of 5 years (20-60%), but occurs rarely (<5%) when infection is acquired in adulthood. 7, 8 Worldwide, most persons with CHB were infected at birth or in early childhood. 9 The highest prevalence of HBsAg (>5%) is in sub-Saharan Africa, East Asia, parts of Balkans, the Pacific Islands and the Amazon Basin. 10 Regional variation exists in the epidemiology of HBV: perinatal or horizontal transmission predominates in sub-Saharan Africa and Asia, whereas in high-income countries transmission is predominantly via injection drug use and high-risk sexual behaviours. 9, 11 As PLHIV live longer due to increased access to antiretroviral therapies, liver disease has emerged as a leading cause of death in PLHIV co-infected with HBV or HCV. 12, 13 Among people with HBsAg, co-infection with HIV results in higher rates of chronicity and occult HBV (HBV-DNA positivity in the absence of HBsAg), accelerated liver disease progression, higher liver-related mortality and decreased treatment response. [14] [15] [16] [17] Co-infection with CHB also increases risk of hepatotoxicity from antiretroviral therapy (ART) three-to five-fold, 18, 19 and cross-resistance between HIV and HBV drugs is common. 20, 21 Fortunately, tenofovir, a drug commonly included in ART regimens, is also the most effective drug for longterm treatment of HBV, leading to long-term HBV viral suppression, reversal of cirrhosis and fibrosis, and reduction in HBV-related mortality. 22 There is a need to establish the global burden of HBsAg co-infection among PLHIV, to characterize the most affected populations and geographical regions, and to inform national and regional screening programmes and clinical management. However, to date, no review has estimated the global burden of HBV co-infection among PLHIV.
Existing estimates suggest approximately 10% of PLHIV have chronic hepatitis B or 2-4 million people, but were based on small numbers of studies with unclear methodology. 17, 23, 24 Other reviews have focussed on specific regions 25 or people who inject drugs (PWID). 11, 26 We therefore undertook a global systematic review of the prevalence and burden of HBsAg in PLHIV.
| ME THODS

| Search strategy and selection criteria
The systematic review was conducted alongside a companion review examining prevalence and burden of HIV-HCV antibody co-infection (consistent with current or past infection) which contains detailed description of the search and synthesis methods. 27 The review was registered with the PROSPERO prospective register of systematic reviews (CRD42019123388).
In brief, we searched eight databases for material that reported prevalence of HBV and HIV, published between 1 January 2002 and 8 April 2018 following PRISMA guidelines. 28 and 'prevalen* OR inciden* OR seroprevalen* OR screening OR surveillance OR population* OR survey* OR epidem* OR data collection OR population sample* OR community survey* OR cohort OR cross-sectional OR longitud* OR follow-up'. Searches were tailored to the search functionality of each database. The reference lists of articles identified as reviews were screened for additional relevant sources.
We included papers with country-level estimates of HBsAg co-infection among an HIV population sample greater than 50, recruited based on their HIV-positive status or other behavioural characteristics, such as injecting drug use. We excluded editorials or reviews containing no primary data, samples recruited based on their HBsAg status or HIV-HBsAg-positive status; studies based on self-reported HIV or HBsAg status, hospital-based studies, or in healthcare workers, organ or tissue donors, or from populations with other co-morbidities such as persons with TB or mental illness, or undergoing interventions that put them at greater risk of co-infection, including those receiving haemodialysis, those with haemophilia, cancer, cardiovascular disease, other co-infections, kidney, liver or neurological diseases.
| Screening and data extraction
Six reviewers (CF, CM, BM, AT, JS and JO) screened each record with a seventh reviewer (LP) consulted when there was no consensus.
Data extracted included the following: study methods; field-work dates; population; recruitment site; sample size; diagnostic assays K E Y W O R D S co-infection, hepatitis B, HIV, systematic review, viral hepatitis used; and prevalence of co-infection. For approximately 10% of included studies, data were double extracted by a second author (EG) to check the accuracy of data extraction.
| Quality assessment
To address concerns of variable quality of studies in previous reviews, we assessed and rated the quality of included studies based on study design and assay quality (Supporting information S1). Studies with larger sample sizes, recruited from multiple sites, recording age and sex or HIV risk factors were scored higher (A); studies with >200 cases from >1 site, with some HIV risk factors recorded but not designed to measure prevalence was scored lower (B); and studies with <200 case from a single site with no risk factors recorded were scored lowest (C). HBsAg assay methods were rated from 0 where no assay type was specified, to up to 3 where a second confirmatory HBsAg assay was done, with or without a neutralisation step. Best estimates were selected for each population group per country based on the highest assay and study design score. Where multiple estimates were available, we applied decision rules to select the best estimate (Supporting information S1).
| Classification of countries according to Global Burden of Disease region
Countries were initially grouped according to the 21 Global Burden of Disease regions, and these were then combined into ten regions to be consistent with previous published reviews on HIV, HBsAg and HCV burden. 11, 27, 29 
| Definition of Population groups
We extracted data on risk behaviours associated with HIV and HBV transmission and populations were categorized according to 
| Data synthesis
We report HIV-HBsAg co-infection prevalence among six population groups (general population, heterosexual and pregnant women, PWID, MSM, children and young people, and other high-risk populations) by country and region, reporting the best estimate and range for each country from all studies. Global and regional estimates of prevalence were derived from the median of the 'best' estimates for that region and presented alongside the 30, 31 we applied median best estimates of HBsAg co-infection prevalence among PLHIV not exposed via injecting drug use from all surveys included from the literature search for MSM, general population and HIV-positive samples of pregnant women or those heterosexually exposed by regions, and overall. Median best estimates of HBsAg co-infection prevalence among HIV-positive PWID were applied to the distribution of PLHIV exposed via injecting drug use, as estimated by UNODC, across regions and overall.
| Role of the funding source
The WHO commissioned this review for the purpose of informing the update of the WHO guidelines on testing for viral hepatitis. 22, 23 The funder contributed to the data collection, analysis, interpretation and writing of the review. All authors had full access to the study data and share final responsibility for the findings submitted for publication. The full dataset and statistical source code used to generate estimates and select best estimates is available from the corresponding author on request. 
| RE SULTS
| Availability of studies and estimates by region and population group
Overall, 80 (41.0%) of 195 countries had estimates. One-third (n = 28) of these countries were from sub-Saharan Africa and 26.3% (n = 21) 
| Rating of study quality and assay method
| Prevalence of HIV-HBsAg co-infection by population group
| General population samples
The mid-point prevalence of HBsAg co-infection among 45 general population samples testing positive for HIV was 7.4% (IQR 1.4%-15.7%) with country-level prevalence estimates shown in Figure 2A .
The highest prevalence was from West and Central Africa at 16.4% compared to 4.4% and 8.8% from South and East Africa, respectively.
Very low prevalence was reported from East Asia (0.4%, one study)
and Latin America (0.9%). There were no general population studies from Europe, North America or Asia Pacific/Australasia. All estimates are summarized in Table 1 with global prevalence maps shown in Figure 2 . 
| Heterosexual and pregnant women
The mid-point prevalence of HBsAg co-infection among 90 studies in PLHIV heterosexual or pregnant women was 6.1% (IQR 3.4%-11.0%) with country-level prevalence estimates shown in Figure 2B .
Prevalence was higher in East Asia (12.8%, one study), West and Central Africa (12.0%), and lowest in Latin America (2.8%), North
Africa and the Middle East (3.4%) and North America (4.2%). Among this population, there were 23 estimates for pregnant women from 15 countries (see footnote to Table 1 for country-specific estimates).
The mid-point prevalence of HBsAg co-infection among 67 studies in heterosexual PLHIV was 8.0% (IQR 5.0%-11.8%) compared to 4.6%
(2.4%-5.9%) among PLHIV pregnant women (data not shown).
| People who inject drugs
The mid-point prevalence among PWID based on 36 studies was 11.8% (IQR 6.0%-16.9%) with country-level prevalence estimates shown in Figure 2C . 35 and Myanmar (41.9%). 34 There was only one study from sub-Saharan Africa (Kenya) which reported a prevalence of 13.9%. 36
| Men who have sex with men
The mid-point prevalence among MSM was 6.1% (IQR 5.0%-9.2%) based on 70 studies with country-level prevalence estimates shown in Figure 2D . Prevalence was highest in South and South-East Asia (10.6%), West and Central Africa (9.2%, one study), followed by East Asia (8.8%) and Latin America (7.2%). Lower prevalences of around 4%-6% were reported from Asia Pacific/Australasia, Europe and North America. There were no studies from East Africa, South Africa or North Africa and the Middle East.
| Other high-risk groups
In addition to the main HIV-exposure categories, there were 243 estimates from samples of PLHIV engaging in mixed sexual and/or injecting risk behaviours (Table S3 ) with country-level prevalence estimates shown in Figure 2E . The point prevalence was 6.4% (IQR 4.3%-9.6%) and was similar across the regions, except for East Asia (15.6%), and West and Central Africa (10.6%).
| Children and young people
There were 22 estimates of HIV-HBsAg co-infection among children and young people from 13 countries (Table S3 ). The mid-point prevalence was 6.8% (IQR 2.5-10.0). Prevalence ranged from 2% to 20% across six estimates from Nigeria [37] [38] [39] [40] [41] [42] and between 0% and 20.5% in South Africa. [43] [44] [45] [46] Extremely high prevalence (43%-46%) was observed in Romania in two studies 47, 48 where HIV infection was acquired nosocomially prior to 1995. A high prevalence (32.6%) was also found in Thailand among young people perinatally infected with HIV (mean age 14 years). 49 48, [55] [56] [57] HIV-exposure categories were not consistently reported.
| Odds of HBsAg positivity among PLHIV compared to HIV-negative persons
Overall 95% CI 0.71-10.25), but not with other population groups. This is summarized in Figure 3 and Table S4 . and Latin America (6%). All other regions account for <5% each ( Table 2 ).
| Global burden of HBV co-infection among PLHIV
| D ISCUSS I ON
This is the first systematic review to provide global, regional and country estimates of prevalence and burden of HBsAg positivity among PLHIV across six population sub-groups; complementing a companion review on HIV-HCV antibody co-infection. 27 We estimate a global prevalence of 7.6% (IQR 5.6%-12.1%) or 2.7 million (IQR 2.0-4.2 million) cases of HIV-HBsAg co-infection. The greatest burden (69% of all cases; 1.9 million) is in sub-Saharan Africa where there is the largest number of PLHIV. This is followed by 12% (355 600) in South and South-East Asia and 6% (68 800) in Latin America.
HBsAg prevalence was broadly similar across different HIVpositive population groups, with a prevalence of 6%-7% reported among general population samples, heterosexually exposed or pregnant women, children, MSM and high-risk populations. Only among PWID was prevalence higher at 11.8%. PWID accounted for only 3% of the global co-infected population, but a much higher proportion in Eastern Europe (45% of cases). We were limited in our ability to make regional comparisons across sub-populations because only two regions (sub-Saharan Africa and South and South-East Asia) had general population data, and there were little data among high-risk populations in sub-Saharan Africa. The most comprehensive data from different regions was among heterosexual or pregnant PLHIV. The prevalence was highest in West and Central Africa (12.0%), and East Asia (12.8%) and lowest in Latin America (2.8%) and North America (4.2%).
Our global estimate of burden of HIV-HBsAg co-infection is broadly consistent with previous estimates of 2-4 million. 24, 25, 58, 59 A review of HIV-HBsAg co-infection in sub-Saharan Africa found a mean prevalence of 12.5% among HIV-positive cohorts, slightly higher than we found, although that study did not disaggregate by HIV-exposure category making comparisons challenging. 25 Our findings broadly reflect existing data on the main routes of transmission of HBV infection. In sub-Saharan Africa, HBV infection is predominantly acquired perinatally or in early childhood, leading to high rates of chronic infection. 4, 60 The contribution of adult acquisition is low, as the majority are already chronically infected or immune. As a result, most people have already been HBV-infected for many years by the time they are exposed to HIV in adulthood, which may explain why the prevalence is similar across different sub-populations. 9 In contrast, in other regions a higher prevalence occurs among PWID and MSM compared to the general population. This was particularly marked in Latin America, with co-infection prevalence of 9.5% and 27% among PWID and MSM, respectively, compared to 0.9% in the general population. This is consistent with co-transmission of HBV and HIV in adulthood in these settings, with much lower transmission of HBV in childhood. 22 Median prevalence and IQRs are calculated across the best estimates for all population groups (except PWID estimates) and countries in each region (for regional estimates) or globally (for 'Total' estimates). Median prevalence and IQRs are calculated across the best PWID estimates for each country in each region (for regional estimates) or globally (for 'Total' estimates) co-infection. Despite this, estimates were available for only 41% of countries, half being in sub-Saharan Africa. Five regional prevalence estimates for different sub-populations were based on data from a single country, possibly unrepresentative of the true regional profile.
Few countries had data for all sub-populations making regional comparisons difficult. We excluded studies that only presented regional-level data, not disaggregated by country, to enable us to observe how prevalence varied by country and risk group within a region and to take account of the differing epidemiology of HIV at a country level.
However, this resulted in the exclusion of large cohorts that aggregate across country and region. One major cohort that reports data across Europe, Israel and Argentina found a comparable prevalence of HIV-HBsAg co-infection (7.1%-8.7%) with similar high prevalence observed in Argentina among PLHIV (exposure group not specified) to the range of prevalence we found among MSM. 61, 62 The quality of studies was also variable. Few studies were based on large multisite surveys, with 40% of sero-surveys being based on data from one city and fewer than 200 persons. In addition, over half of studies provided no details of the assay type and testing protocol; with much of the remainder using a recent HBsAg assay but without confirmatory HBsAg testing, possibly overestimating the infected population. In general, WHO does not recommend the use of a second confirmatory HBsAg assay for diagnosis of CHB infection (23) . We also did not exclude populations based on receiving ART, with few studies reporting the prevalence of ART making it difficult to adjust for the effects of treatment. The use of tenofovir-based ART regimens may have reduced detection of HBsAg among some samples. 63 Finally, we have not taken into account increases in both ART coverage and the use of tenofovir-based ART regimens that may result in lower levels of co-infection in later years.
Our findings have important programmatic implications. First, universal infant and perinatal HBV vaccination remains the key strategy for preventing mother-to-child transmission and controlling the HBV epidemic. Although high uptake of infant vaccination has been achieved, leading to substantial decreases in incidence in recent years, HBV birth-dose vaccination is being implemented by less than half of countries, and only 9/48 of countries in Africa. 4 Rates of adult vaccination also remain low, with <3% of countries routinely vaccinating high-risk populations (PWID, MSM, sex workers and prisoners). 22 Our findings highlight the importance of targeting PLHIV, especially high-risk groups and children for testing, catch-up HBV vaccination and other preventative interventions. 64 Second, the global scale-up of HIV treatment for PLHIV using a tenofovir-based ART regimen represents a major opportunity for achieving global targets towards hepatitis B elimination in PLHIV, by simultaneously treating those who have chronic and HIV co-infection so reducing mother-to-child transmission of HBV alongside HIV. 65 ART coverage is now approximately 50% in most countries and encouragingly coverage in eastern and southern Africa is higher than the global average, 66 with 60% of persons on ART receiving a tenofovir-based regimen. 67 Our findings clearly show the need to scale-up tenofovir-based ART to address HIV-HBsAg co-infection, particularly focusing on sub-Saharan Africa.
ACK N OWLED G EM ENTS
The authors wish to thank Jane Falconer (Information Services Librarian at the LSHTM) for her assistance with the search strategy and Yvan Hutin for inputs on the manuscript.
CO N FLI C T S O F I NTE R E S T
No conflicts of interest to declare.
AUTH O R CO NTR I B UTO R S
PE conceived the study proposal. LP, PV and PE developed the overall methods for use in the report. LP developed the methodology and oversaw the search and data extraction for the report. Clare E. French https://orcid.org/0000-0002-6943-7353
Keith Sabin https://orcid.org/0000-0002-2290-8621
Adam Trickey https://orcid.org/0000-0003-3462-2898 Philippa Easterbrook https://orcid.org/0000-0002-2603-5418
Peter Vickerman https://orcid.org/0000-0002-8291-5890
